Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.

ABSTRACT:

Introduction

Psychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Limited data exist on the most effective therapies.

Methods

Retrospective cohort study comparing patients with PD or DLB initiated on quetiapine or pimavanserin for psychosis. Primary outcome was time to discontinuation of pimavanserin or quetiapine using Kaplan-Meier survival analysis. We hypothesized the rate of antipsychotic discontinuation would be lower in the pimavanserin group. Subjects were included if the indication for treatment was psychosis and excluded if there was a history of major mental illness or no follow up data were available.

Results

Forty-seven patients were included in the quetiapine cohort and 45 in the pimavanserin cohort. Patien

SUBMITTER: Horn S 

PROVIDER: S-EPMC7061324 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature